Absence of a role for phosphorylation in the tau pathology of Alzheimer’s disease

Biomolecules

Volumn 6, Issue 2, 2016, Pages

  Lai, Robert Y K ^a   Harrington, Charles R ^b   Wischik, Claude M ^b  

^a MRC LABORATORY OF MOLECULAR BIOLOGY   (United Kingdom)

^b UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

Alzheimer s disease; Phosphorylation; Protein aggregation; Tau protein

Indexed keywords

TAU PROTEIN; PROTEIN BINDING; RECOMBINANT PROTEIN; TUBULIN; WATER;

ADULT; ALZHEIMER DISEASE; ARTICLE; BINDING AFFINITY; CARBOXY TERMINAL SEQUENCE; CONFORMATIONAL TRANSITION; HUMAN; HUMAN TISSUE; IMMUNOELECTRON MICROSCOPY; KARYOTYPE; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROCESS OPTIMIZATION; PROTEIN AGGREGATION; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION; WESTERN BLOTTING; BIOSYNTHESIS; CHEMISTRY; GENETICS; ISOLATION AND PURIFICATION; KINETICS; METABOLISM; PATHOLOGY; PHOSPHORYLATION; PROTEIN DOMAIN;

ALZHEIMER DISEASE; HUMANS; KINETICS; PHOSPHORYLATION; PROTEIN BINDING; PROTEIN DOMAINS; RECOMBINANT PROTEINS; TAU PROTEINS; TUBULIN; WATER;

EID: 85012066300     PISSN: None     EISSN: 2218273X     Source Type: Journal    
DOI: 10.3390/biom6020019     Document Type: Article

References (63)

1. Harrington, C.R.; Mukaetova-Ladinska, E.B.; Hills, R.; Edwards, P.C.; Montejo de Garcini, E.; Novak, M.; Wischik, C.M. Measurement of distinct immunochemical presentations of tau protein in Alzheimer disease. PNAS 1991, 88, 5842-5846. [CrossRef] [PubMed]
2. Drubin, D.G.; Kirschner, M.W. Tau protein function in living cells. J. Cell Biol. 1986, 103, 2739-2746. [CrossRef] [PubMed]
3. Alzheimer, A. Über eine eigenartige Erkrankung der Hirnrinde. Allg. Z. Psych. Psych. Gerich. Med. 1907, 64, 146-148.
4. Nelson, P.T.; Alafuzoff, I.; Bigio, E.H.; Bouras, C.; Braak, H.; Cairns, N.J.; Castellani, R.J.; Crain, B.J.; Davies, P.; Tredici, K.D., et al. Correlation of Alzheimer disease neuropathologic changes with cognitive status: A review of the literature. J. Neuropathol. Exp. Neurol. 2012, 71, 362-381. [CrossRef] [PubMed]
5. Wischik, C.M.; Harrington, C.R.; Storey, J.M.D. Tau-aggregation inhibitor therapy for Alzheimer’s disease. Biochem. Pharmacol. 2014, 88, 529-539. [CrossRef] [PubMed]
6. Fodero-Tavoletti, M.; Furumoto, S.; Taylor, L.; McLean, C.; Mulligan, R.; Birchall, I.; Harada, R.; Masters, C.; Yanai, K.; Kudo, Y., et al. Assessing THK523 selectivity for tau deposits in Alzheimer’s disease and non Alzheimer’s disease tauopathies. Alzheimers Res. Ther. 2014. [CrossRef] [PubMed]
7. Xia, C.F.; Arteaga, J.; Chen, G.; Gangadharmath, U.; Gomez, L.F.; Kasi, D.; Lam, C.; Liang, Q.W.; Liu, C.H.; Mocharla, V.P., et al. F-18 T807, a novel tau positron emission tomography imaging agent for Alzheimer’s disease. Alzheimer’s Dement. 2013, 9, 666-676. [CrossRef] [PubMed]
8. Cisek, K.; Cooper, G.L.; Huseby, C.J.; Kuret, J. Structure and mechanism of action of tau aggregation inhibitors. Curr. Alzheimer Res. 2014, 11, 918-927. [CrossRef] [PubMed]
9. Lee, V.M.-Y.; Balin, B.J.; Otvos, L.J., Jr.; Trojanowski, J.Q. A68: A major subunit of paired helical filaments and derivatized forms of normal tau. Science 1991, 251, 675-678. [CrossRef] [PubMed]
10. Goedert, M.; Spillantini, M.G.; Cairns, N.J.; Crowther, R.A. Tau proteins of Alzheimer paired helical filaments: Abnormal phosphorylation of all six brain isoforms. Neuron 1992, 8, 159-168. [CrossRef]
11. Lindwall, G.; Cole, R.D. Phosphorylation affects the ability of tau protein to promote microtubule assembly. J. Biol. Chem. 1984, 259, 5301-5305. [PubMed]
12. Biernat, J.; Gustke, N.; Drewes, G.; Mandelkow, E.-M.; Mandelkow, E. Phosphorylation of Ser262 strongly reduces binding of tau to microtubules: Distinction between PHF-like immunoreactivity and microtubule binding. Neuron 1993, 11, 153-163. [CrossRef]
13. Alonso, A.D.; Zaidi, T.; Grundke-Iqbal, I.; Iqbal, K. Role of abnormally phosphorylated tau in the breakdown of microtubules in Alzheimer’s disease. PNAS 1994, 91, 5562-5566. [CrossRef] [PubMed]
14. Tseng, H.-C.; Lu, Q.; Graves, D.J. Phosphorylated tau can promote tubulin assembly. PNAS 1999, 96, 9503-9508. [CrossRef] [PubMed]
15. Buee, L.; Troquier, L.; Burnouf, S.; Belarbi, K.; van der Jeugd, A.; Ahmed, T.; Fernandez-Gomez, F.; Caillierez, R.; Grosjean, M.E.; Begard, S., et al. From tau phosphorylation to tau aggregation: What about neuronal death? Biochem. Soc. Trans. 2010, 38, 967-972. [CrossRef] [PubMed]
16. Iqbal, K.; Alonso Adel, C.; Chen, S.; Chohan, M.O.; El-Akkad, E.; Gong, C.X.; Khatoon, S.; Li, B.; Liu, F.; Rahman, A., et al. Tau pathology in Alzheimer disease and other tauopathies. Biochim. Biophys. Acta 2005, 1739, 198-210. [CrossRef] [PubMed]
17. Wischik, C.M.; Edwards, P.C.; Lai, R.Y.K.; Gertz, H.-J.; Xuereb, J.H.; Paykel, E.S.; Brayne, C.; Huppert, F.A.; Mukaetova-Ladinska, E.B.; Mena, R., et al. Quantitative analysis of tau protein in paired helical filament preparations: Implications for the role of tau protein phosphorylation in PHF assembly in Alzheimer’s disease. Neurobiol. Aging 1995, 16, 409-431. [CrossRef]
18. Mukaetova-Ladinska, E.B.; Garcia-Sierra, F.; Hurt, J.; Gertz, H.J.; Xuereb, J.H.; Hills, R.; Brayne, C.; Huppert, F.A.; Paykel, E.S.; McGee, M., et al. Staging of cytoskeletal and b-amyloid changes in human isocortex reveals biphasic synaptic protein response during progression of Alzheimer’s disease. Am. J. Pathol. 2000, 157, 623-636. [CrossRef]
19. Wischik, C.M.; Lai, R.Y.K.; Harrington, C.R. Modelling prion-like processing of tau protein in Alzheimer’s disease for pharmaceutical development. In Brain Microtubule Associated Proteins: Modifications in Disease; Avila, J., Brandt, R., Kosik, K.S., Eds.; Harwood Academic Publishers: Amsterdam, The Netherlands, 1997; pp. 185-241.
20. Novak, M.; Jakes, R.; Edwards, P.C.; Milstein, C.; Wischik, C.M. Difference between the tau protein of Alzheimer paired helical filament core and normal tau revealed by epitope analysis of mAbs 423 and 7.51. PNAS 1991, 88, 5837-5841. [CrossRef] [PubMed]
21. Bondareff, W.; Harrington, C.; Wischik, C.M.; Hauser, D.L.; Roth, M. Immunohistochemical staging of neurofibrillary degeneration in Alzheimer’s disease. J. Neuropathol. Exp. Neurol. 1994, 53, 158-164. [CrossRef] [PubMed]
22. Bondareff, W.; Wischik, C.M.; Novak, M.; Roth, M. Sequestration of tau by granulovacuolar degeneration in Alzheimer’s disease. Am. J. Pathol. 1991, 139, 641-647. [PubMed]
23. Wischik, C.M.; Novak, M.; Thøgersen, H.C.; Edwards, P.C.; Runswick, M.J.; Jakes, R.; Walker, J.E.; Milstein, C.; Roth, M.; Klug, A. Isolation of a fragment of tau derived from the core of the paired helical filament of Alzheimer’s disease. PNAS 1988, 85, 4506-4510. [CrossRef] [PubMed]
24. Mena, R.; Edwards, P.C.; Harrington, C.R.; Mukaetova-Ladinska, E.B.; Wischik, C.M. Staging the pathological assembly of truncated tau protein into paired helical filaments in Alzheimer’s disease. Acta Neuropathol. 1996, 91, 633-641. [CrossRef] [PubMed]
25. Mena, R.; Edwards, P.; Pérez-Olvera, O.; Wischik, C.M. Monitoring pathological assembly of tau and b-amyloid proteins in Alzheimer’s disease. Acta Neuropathol. 1995, 89, 50-56. [CrossRef] [PubMed]
26. Jakes, R.; Novak, M.; Davison, M.; Wischik, C.M. Identification of 3- and 4-repeat tau isoforms within the PHF in Alzheimer’s disease. EMBO J. 1991, 10, 2725-2729. [PubMed]
27. Wischik, C.M.; Edwards, P.C.; Lai, R.Y.K.; Roth, M.; Harrington, C.R. Selective inhibition of Alzheimer disease-like tau aggregation by phenothiazines. PNAS 1996, 93, 11213-11218. [CrossRef] [PubMed]
28. Arrasate, M.; Pérez, M.; Valpuesta, J.M.; Avila, J. Role of glycosaminoglycans in determining the helicity of paired helical filaments. Am. J. Pathol. 1997, 151, 1115-1122. [PubMed]
29. Friedhoff, P.; von Bergen, M.; Mandelkow, E.-M.; Davies, P.; Mandelkow, E. A nucleated assembly of Alzheimer paired helical filaments. PNAS 1998, 95, 15712-15717. [CrossRef] [PubMed]
30. Goedert, M.; Jakes, R.; Spillantini, M.G.; Hasegawa, M.; Smith, M.J.; Crowther, R.A. Assembly of microtubule-associated protein tau into Alzheimer-like filaments induced by sulphated glycosaminoglycans. Nature 1996, 383, 550-553. [CrossRef] [PubMed]
31. Hasegawa, M.; Crowther, R.A.; Jakes, R.; Goedert, M. Alzheimer-like changes in microtubule-associated protein tau induced by sulfated glycosaminoglycans: inhibition of microtubule binding, stimulation of phosphorylation, and filament assembly depend on the degree of sulfation. J. Biol. Chem. 1997, 272, 33118-33124. [CrossRef] [PubMed]
32. Pérez, M.; Valpuesta, J.M.; Medina, M.; Montejo de Garcini, E.; Avila, J. Polymerization of t into filaments in the presence of heparin: the minimal sequence required for t-t interaction. J. Neurochem. 1996, 67, 1183-1190. [CrossRef] [PubMed]
33. Goedert, M.; Jakes, R. Expression of separate isoforms of human tau protein: Correlation with the tau pattern in brain and effects on tubulin polymerisation. EMBO J. 1990, 9, 4225-4230. [PubMed]
34. Goedert, M.; Jakes, R.; Crowther, R.A.; Six, J.; Lübke, U.; Vandermeeren, M.; Cras, P.; Trojanowski, J.Q.; Lee, V.M.-J. The abnormal phosphorylation of tau protein at Ser-202 in Alzheimer’s disease recapitulates phosphorylation during development. PNAS 1993, 90, 5066-5070. [CrossRef] [PubMed]
35. Novak, M.; Kabat, J.; Wischik, C.M. Molecular characterization of the minimal protease resistant tau unit of the Alzheimer’s disease paired helical filament. EMBO J. 1993, 12, 365-370. [PubMed]
36. Biernat, J.; Mandelkow, E.-M.; Schröter, C.; Lichtenberg-Kraag, B.; Steiner, B.; Berling, B.; Meyer, H.; Mercken, M.; Vandermeeren, A.; Goedert, M., et al. The switch of tau protein to an Alzheimer-like state includes the phosphorylation of two serine-proline motifs upstream of the microtubule binding region. EMBO J. 1992, 11, 1593-1597. [PubMed]
37. Harrington, C.R.; Edwards, P.C.; Wischik, C.M. Competitive ELISA for measurement of tau proteins in Alzheimer’s disease. J. Immunol. Meth. 1990, 134, 261-271. [CrossRef]
38. Goedert, M.; Jakes, R.; Vanmechelen, E. Monoclonal antibody AT8 recognises tau protein phosphorylated at both serine 202 and threonine 205. Neurosci. Lett. 1995, 189, 167-170. [CrossRef]
39. Schneider, A.; Biernat, J.; von Bergen, M.; Mandelkow, E.; Mandelkow, E.-M. Phosphorylation that detaches tau protein from microtubules (Ser262, Ser214) also protects it against aggregation into Alzheimer paired helical filaments. Biochemistry 1999, 38, 3549-3558. [CrossRef] [PubMed]
40. Kanemaru, K.; Takio, K.; Miura, R.; Titani, K.; Ihara, Y. Fetal-type phosphorylation of the t in paired helical filaments. J. Neurochem. 1992, 58, 1667-1675. [CrossRef] [PubMed]
41. Bramblett, G.T.; Goedert, M.; Jakes, R.; Merrick, S.E.; Trojanowski, J.Q.; Lee, V.M.-Y. Abnormal tau phosphorylation at Ser396 in Alzheimer’s disease recapitulates development and contributes to reduced microtubule binding. Neuron 1993, 10, 1089-1099. [CrossRef]
42. Akoury, E.; Pickhardt, M.; Gajda, M.; Biernat, J.; Mandelkow, E.; Zweckstetter, M. Mechanistic basis of phenothiazine-driven inhibition of tau aggregation. Angew. Chem. Int. Ed. 2013, 52, 3511-3515. [CrossRef] [PubMed]
43. Huvent, I.; Kamah, A.; Cantrelle, F.-X.; Barois, N.; Slomianny, C.; Smet-Nocca, C.; Landrieu, I.; Lippens, G. A functional fragment of Tau forms fibers without the need for an intermolecular cysteine bridge. Biochem. Biophys. Res. Commun. 2014, 445, 299-303. [CrossRef] [PubMed]
44. Crowther, R.A.; Olesen, O.F.; Jakes, R.; Goedert, M. The microtubule binding repeats of tau protein assemble into filaments like those found in Alzheimer’s disease. FEBS Lett. 1992, 309, 199-202. [CrossRef]
45. Lai, R.Y.K.; Gertz, H.-J.; Wischik, D.J.; Xuereb, J.H.; Mukaetova-Ladinska, E.B.; Harrington, C.R.; Edwards, P.C.; Mena, R.; Paykel, E.S.; Brayne, C., et al. Examination of phosphorylated tau protein as a PHF-precursor at early stage Alzheimer’s disease. Neurobiol. Aging 1995, 16, 433-445. [CrossRef]
46. Duyckaerts, C. Tau pathology in children and young adults: can you still be unconditionally baptist? Acta Neuropathol. 2011, 121, 145-147. [CrossRef] [PubMed]
47. Fasulo, L.; Visintin, M.; Novak, M.; Cattaneo, A. Tau truncation in Alzheimer’s disease: Expression of a fragment encompassing PHF core tau induces apoptosis in COS cells. Alzheimer’s Rep. 1998, 1, 25-32.
48. Fasulo, L.; Ovecka, M.; Kabát, J.; Bradbury, A.; Novák, M.; Cattaneo, A. Overexpression of Alzheimer’s PHF core tau fragments: Implications for the tau truncation hypothesis. Alzheimer’s Res. 1996, 2, 195-200.
49. Schweers, O.; Mandelkow, E.-M.; Biernat, J.; Mandelkow, E. Oxidation of cysteine-322 in the repeat domain of microtubule-associated protein t controls the in vitro assembly of paired helical filaments. PNAS 1995, 92, 8463-8467. [CrossRef] [PubMed]
50. Braak, H.; Del Tredici, K. The pathological process underlying Alzheimer’s disease in individuals under thirty. Acta Neuropathol. 2011, 121, 171-181. [CrossRef] [PubMed]
51. Braak, H.; Braak, E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991, 82, 239-259. [CrossRef] [PubMed]
52. Frost, B.; Jacks, R.L.; Diamond, M.I. Propagation of tau misfolding from the outside to the inside of a cell. J. Biol. Chem. 2009, 284, 12845-12852. [CrossRef] [PubMed]
53. Clavaguera, F.; Akatsu, H.; Fraser, G.; Crowther, R.A.; Frank, S.; Hench, J.; Probst, A.; Winkler, D.T.; Reichwald, J.; Staufenbiel, M., et al. Brain homogenates from human tauopathies induce tau inclusions in mouse brain. PNAS 2013, 110, 9535-9540. [CrossRef] [PubMed]
54. De Calignon, A.; Polydoro, M.; Suárez-Calvet, M.; William, C.; Adamowicz, D.H.; Kopeikina, K.J.; Pitstick, R.; Sahara, N.; Ashe, K.H.; Carlson, G.A., et al. Propagation of tau pathology in a model of early Alzheimer’s disease. Neuron 2012, 73, 685-697. [CrossRef] [PubMed]
55. Liu, L.; Drouet, V.; Wu, J.W.; Witter, M.P.; Small, S.A.; Clelland, C.; Duff, K. Trans-synaptic spread of tau pathology in vivo. PLoS ONE 2012, 7, e31302. [CrossRef] [PubMed]
56. Clavaguera, F.; Bolmont, T.; Crowther, R.A.; Abramowski, D.; Frank, S.; Probst, A.; Fraser, G.; Stalder, A.K.; Beibel, M.; Staufenbiel, M., et al. Transmission and spreading of tauopathy in transgenic mouse brain. Nat. Cell Biol. 2009, 11, 909-914. [CrossRef] [PubMed]
57. Boluda, S.; Iba, M.; Zhang, B.; Raible, K.M.; Lee, V.M.Y.; Trojanowski, J.Q. Differential induction and spread of tau pathology in young PS19 tau transgenic mice following intracerebral injections of pathological tau from Alzheimer’s disease or corticobasal degeneration brains. Acta Neuropathol. 2015, 129, 221-237. [CrossRef] [PubMed]
58. Falcon, B.; Cavallini, A.; Angers, R.; Glover, S.; Murray, T.K.; Barnham, L.; Jackson, S.; O’Neill, M.J.; Isaacs, A.M.; Hutton, M.L., et al. Conformation determines the seeding potencies of native and recombinant tau aggregates. J. Biol. Chem. 2015, 290, 1049-1065. [CrossRef] [PubMed]
59. Sanders, D.W.; Kaufman, S.K.; DeVos, S.L.; Sharma, A.M.; Mirbaha, H.; Li, A.; Barker, S.J.; Foley, A.C.; Thorpe, J.R.; Serpell, L.C., et al. Distinct tau prion strains propagate in cells and mice and define different tauopathies. Neuron 2014, 82, 1271-1288. [CrossRef] [PubMed]
60. Lewis, J.; Dickson, D.W. Propagation of tau pathology: Hypotheses, discoveries, and yet unresolved questions from experimental and human brain studies. Acta Neuropathol. 2016, 131, 27-48. [CrossRef] [PubMed]
61. Goedert, M. Alzheimer’s and Parkinson’s diseases: The prion concept in relation to assembled Aβ, tau, and α-synuclein. Science 2015. [CrossRef] [PubMed]
62. Pedersen, J.T.; Sigurdsson, E.M. Tau immunotherapy for Alzheimer’s disease. Trends Mol. Med. 2015, 21, 394-402. [CrossRef] [PubMed]
63. Kampers, T.; Friedhoff, P.; Biernat, J.; Mandelkow, E.-M.; Mandelkow, E. RNA stimulates aggregation of microtubule-associated protein tau into Alzheimer-like paired helical filaments. FEBS Lett. 1996, 399, 344-349. [CrossRef]